* Assembly Biosciences Inc ASMB.OQ ASMB.O is expected
to show
no change in quarterly revenue when it reports results on March
20 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Assembly Biosciences Inc
is
for a loss of $2.88 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Assembly
Biosciences Inc is $36.00, above its last closing price
of $12.17.
This summary was machine generated March 18 at 11:06 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)